Topic Editors

Department of Biochemistry and Molecular Genetics, University of Colorado, Denver, CO 80045, USA
Department of Biochemistry and Molecular Genetics, and RNA BioScience Initiative, University of Colorado Anschutz Medical Campus, Aurora, CO 80045, USA
Department of Biochemistry and Molecular Genetics, University of Colorado Anschutz Medical Campus, Aurora, CO 80045, USA

Emerging Aspects in Drug Discovery

Abstract submission deadline
1 September 2023
Manuscript submission deadline
1 December 2023
Viewed by
7347

Topic Information

Dear Colleagues,

With the large number of diseases still present worldwide that remain difficult to treat, drug discovery is a pressing endeavor. However, finding effective therapeutic agents remains onerous and time consuming. How could new approaches, technologies, and perhaps targets facilitate the process of identifying, characterizing, developing, and marketing drugs? This Topic on “Emerging Aspects in Drug Discovery” welcomes submissions of research and review articles that touch upon—but are not limited to—the following areas: novel screening strategies and synthetic chemistry approaches, as well as emerging drug targets which can be any macromolecule, RNA, DNA, or protein. We hope this Topic will serve as a springboard for a continuous increase in the rates of approved drugs for treating different diseases.

Dr. Morkos Henen
Dr. Quentin Vicens
Dr. Beat Rolf Vögeli
Topic Editors

Keywords

  • compound development
  • drug discovery
  • high-throughput screening
  • natural compounds
  • structure–activity relationship
  • structure-based drug design
  • synthetic chemistry
  • target identification and validation

Participating Journals

Journal Name Impact Factor CiteScore Launched Year First Decision (median) APC
Antibiotics
antibiotics
5.222 3.9 2012 12.6 Days 2200 CHF Submit
International Journal of Molecular Sciences
ijms
6.208 6.9 2000 15.9 Days 2500 CHF Submit
Magnetochemistry
magnetochemistry
3.336 3.0 2015 12.5 Days 1800 CHF Submit
Marine Drugs
marinedrugs
6.085 8.1 2003 13.6 Days 2500 CHF Submit
Molecules
molecules
4.927 5.9 1996 13.4 Days 2300 CHF Submit

Preprints is a platform dedicated to making early versions of research outputs permanently available and citable. MDPI journals allow posting on preprint servers such as Preprints.org prior to publication. For more details about reprints, please visit https://www.preprints.org.

Published Papers (5 papers)

Order results
Result details
Journals
Select all
Export citation of selected articles as:
Article
Group I Intron as a Potential Target for Antifungal Compounds: Development of a Trans-Splicing High-Throughput Screening Strategy
Molecules 2023, 28(11), 4460; https://doi.org/10.3390/molecules28114460 - 31 May 2023
Viewed by 208
Abstract
The search for safe and efficient new antifungal compounds for agriculture has led to more efforts in finding new modes of action. This involves the discovery of new molecular targets, including coding and non-coding RNA. Rarely found in plants and animals but present [...] Read more.
The search for safe and efficient new antifungal compounds for agriculture has led to more efforts in finding new modes of action. This involves the discovery of new molecular targets, including coding and non-coding RNA. Rarely found in plants and animals but present in fungi, group I introns are of interest as their complex tertiary structure may allow selective targeting using small molecules. In this work, we demonstrate that group I introns present in phytopathogenic fungi have a self-splicing activity in vitro that can be adapted in a high-throughput screening to find new antifungal compounds. Ten candidate introns from different filamentous fungi were tested and one group ID intron found in F. oxysporum showed high self-splicing efficiency in vitro. We designed the Fusarium intron to act as a trans-acting ribozyme and used a fluorescence-based reporter system to monitor its real time splicing activity. Together, these results are opening the way to study the druggability of such introns in crop pathogen and potentially discover small molecules selectively targeting group I introns in future high-throughput screenings. Full article
(This article belongs to the Topic Emerging Aspects in Drug Discovery)
Show Figures

Figure 1

Article
A Novel Rabbit Anti-Myoglobin Monoclonal Antibody’s Potential Application in Rhabdomyolysis Associated Acute Kidney Injury
Int. J. Mol. Sci. 2023, 24(9), 7822; https://doi.org/10.3390/ijms24097822 - 25 Apr 2023
Viewed by 507
Abstract
Myoglobin (Mb) is the main constituent of vertebrate skeletal muscle and myocardium and plays an essential role in oxygen binding, storage, transport, and earliest disease diagnosis. This study focuses on preparing the novel recombinant rabbit anti-Mb monoclonal antibody and applying it to a [...] Read more.
Myoglobin (Mb) is the main constituent of vertebrate skeletal muscle and myocardium and plays an essential role in oxygen binding, storage, transport, and earliest disease diagnosis. This study focuses on preparing the novel recombinant rabbit anti-Mb monoclonal antibody and applying it to a diagnosis of Mb deposition in rhabdomyolysis-associated acute kidney injury (RM-AKI). The full-length coding sequence of rat Mb was cloned and expressed, and the high-quality and titer rabbit anti-Mb polyclonal antibodies were produced by the immunogen His-Mb fusion protein. A new hybridoma cell was obtained by hybridoma screening technology. With the help of DNA sequencing and a molecular clonal, anti-Mb monoclonal antibody heavy and light chains expression plasmid was constructed. Finally, the recombinant rabbit anti-Mb monoclonal antibody with extraordinarily high affinity (KD = 1.21 pM) was obtained. Meanwhile, it had broad species reactivity (mouse, rat, human, and horse) and good tissue specificity (skeletal muscle and myocardium). It also had a very good performance in western blotting, immunohistochemistry, and immunofluorescence assay to detect the Mb level in the kidney, myocardium, and skeletal muscle of RM-AKI. This study will be significantly helpful for Mb-associated disease diagnosis, and pathogenesis exploration, and further may act as a neutralizing antibody for disease treatment. Full article
(This article belongs to the Topic Emerging Aspects in Drug Discovery)
Show Figures

Figure 1

Article
Machine Learning Models to Predict Protein–Protein Interaction Inhibitors
Molecules 2022, 27(22), 7986; https://doi.org/10.3390/molecules27227986 - 17 Nov 2022
Cited by 1 | Viewed by 1616
Abstract
Protein–protein interaction (PPI) inhibitors have an increasing role in drug discovery. It is hypothesized that machine learning (ML) algorithms can classify or identify PPI inhibitors. This work describes the performance of different algorithms and molecular fingerprints used in chemoinformatics to develop a classification [...] Read more.
Protein–protein interaction (PPI) inhibitors have an increasing role in drug discovery. It is hypothesized that machine learning (ML) algorithms can classify or identify PPI inhibitors. This work describes the performance of different algorithms and molecular fingerprints used in chemoinformatics to develop a classification model to identify PPI inhibitors making the codes freely available to the community, particularly the medicinal chemistry research groups working with PPI inhibitors. We found that classification algorithms have different performances according to various features employed in the training process. Random forest (RF) models with the extended connectivity fingerprint radius 2 (ECFP4) had the best classification abilities compared to those models trained with ECFP6 o MACCS keys (166-bits). In general, logistic regression (LR) models had lower performance metrics than RF models, but ECFP4 was the representation most appropriate for LR. ECFP4 also generated models with high-performance metrics with support vector machines (SVM). We also constructed ensemble models based on the top-performing models. As part of this work and to help non-computational experts, we developed a pipeline code freely available. Full article
(This article belongs to the Topic Emerging Aspects in Drug Discovery)
Show Figures

Figure 1

Review
ESKAPE Pathogens: Looking at Clp ATPases as Potential Drug Targets
Antibiotics 2022, 11(9), 1218; https://doi.org/10.3390/antibiotics11091218 - 08 Sep 2022
Viewed by 2208
Abstract
Bacterial antibiotic resistance is rapidly growing globally and poses a severe health threat as the number of multidrug resistant (MDR) and extensively drug-resistant (XDR) bacteria increases. The observed resistance is partially due to natural evolution and to a large extent is attributed to [...] Read more.
Bacterial antibiotic resistance is rapidly growing globally and poses a severe health threat as the number of multidrug resistant (MDR) and extensively drug-resistant (XDR) bacteria increases. The observed resistance is partially due to natural evolution and to a large extent is attributed to antibiotic misuse and overuse. As the rate of antibiotic resistance increases, it is crucial to develop new drugs to address the emergence of MDR and XDR pathogens. A variety of strategies are employed to address issues pertaining to bacterial antibiotic resistance and these strategies include: (1) the anti-virulence approach, which ultimately targets virulence factors instead of killing the bacterium, (2) employing antimicrobial peptides that target key proteins for bacterial survival and, (3) phage therapy, which uses bacteriophages to treat infectious diseases. In this review, we take a renewed look at a group of ESKAPE pathogens which are known to cause nosocomial infections and are able to escape the bactericidal actions of antibiotics by reducing the efficacy of several known antibiotics. We discuss previously observed escape mechanisms and new possible therapeutic measures to combat these pathogens and further suggest caseinolytic proteins (Clp) as possible therapeutic targets to combat ESKAPE pathogens. These proteins have displayed unmatched significance in bacterial growth, viability and virulence upon chronic infection and under stressful conditions. Furthermore, several studies have showed promising results with targeting Clp proteins in bacterial species, such as Mycobacterium tuberculosis, Staphylococcus aureus and Bacillus subtilis. Full article
(This article belongs to the Topic Emerging Aspects in Drug Discovery)
Show Figures

Figure 1

Article
New Benzimidazoles Targeting Breast Cancer: Synthesis, Pin1 Inhibition, 2D NMR Binding, and Computational Studies
Molecules 2022, 27(16), 5245; https://doi.org/10.3390/molecules27165245 - 17 Aug 2022
Viewed by 1210
Abstract
Benzimidazole derivatives are known to be key players in the development of novel anticancer agents. Herein, we aimed to synthesize novel derivatives to target breast cancer. A new series of benzimidazole derivatives conjugated with either six- and five-membered heterocyclic ring or pyrazanobenzimidazoles and [...] Read more.
Benzimidazole derivatives are known to be key players in the development of novel anticancer agents. Herein, we aimed to synthesize novel derivatives to target breast cancer. A new series of benzimidazole derivatives conjugated with either six- and five-membered heterocyclic ring or pyrazanobenzimidazoles and pyridobenzimidazole linkers were synthesized yielding compounds 58 and 1014, respectively. Structure elucidation of the newly synthesized compounds was achieved through microanalytical analyses and different spectroscopic techniques (1H, 13C-APT and 1H–1H COSY and IR) in addition to mass spectrometry. A biological study for the newly synthesized compounds was performed against breast cancer cell lines (MCF-7), and the most active compounds were further subjected to normal Human lung fibroblast (WI38) which indicates their safety. It was found that most of them exhibit high cytotoxic activity against breast cancer (MCF-7) and low cytotoxic activity against normal (WI38) cell lines. Compounds 5, 8, and 12, which possess the highest anti-breast cancer activity against the MCF-7 cell line, were selected for Pin1 inhibition assay using tannic acid as a reference drug control. Compound 8 was examined for its effect on cell cycle progression and its ability to apoptosis induction. Mechanistic evaluation of apoptosis induction was demonstrated by triggering intrinsic apoptotic pathways via inducing ROS accumulation, increasing Bax, decreasing Bcl-2, and activation of caspases 6, 7, and 9. Binding to 15N-labeled Pin1 enzyme was performed using state-of-the-art 15N–1H HSQC NMR experiments to describe targeting breast cancer on a molecular level. In conclusion, the NMR results demonstrated chemical shift perturbation (peak shifting or peak disappearance) upon adding compound 12 indicating potential binding. Molecular docking using ‘Molecular Operating Environment’ software was extremely useful to elucidate the binding mode of active derivatives via hydrogen bonding. Full article
(This article belongs to the Topic Emerging Aspects in Drug Discovery)
Show Figures

Graphical abstract

Back to TopTop